Study summary
A complement-blocking antibody was stopped for futility in refractory CIDP
What was tested
Riliprubart, an antibody blocking the complement protein C1s, against placebo, for CIDP that had not responded to standard treatments.
What they found
- An independent committee found the trial unlikely to show enough benefit.
- No new safety concerns were seen.
- A second phase 3, VITALIZE, compares riliprubart with immunoglobulin and continues.
What it means
A setback for complement blockers in the hardest-to-treat CIDP.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.